We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Doubles Down on Potential Alzheimer’s Drug as Competitors’ Drugs Fail
Roche Doubles Down on Potential Alzheimer’s Drug as Competitors’ Drugs Fail
September 10, 2012
In a field with multi-billion dollar potential, Roche is more than doubling the size of its Phase II/III clinical trial for what it considers the most advanced monoclonal antibody (mAb) in development to treat early Alzheimer’s disease (AD).